Telomir Pharmaceuticals (TELO) News Today $2.55 -0.01 (-0.39%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Telomir Pharmaceuticals, Inc. (TELO)March 21, 2025 | finance.yahoo.comTELO Study Shows Cancer-Related BreakthroughMarch 19, 2025 | msn.comTelomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal modelMarch 19, 2025 | msn.comTelomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study ShowsMarch 19, 2025 | benzinga.comTelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in FebruaryTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 1,720,000 shares, a growth of 34.4% from the January 31st total of 1,280,000 shares. Currently, 10.1% of the company's shares are short sold. Based on an average daily trading volume, of 192,900 shares, the short-interest ratio is presently 8.9 days.March 4, 2025 | marketbeat.comRodman & Renshaw Begins Coverage on Telomir Pharmaceuticals (NASDAQ:TELO)Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $15.00 target price for the company.February 22, 2025 | marketbeat.comZacks Small Cap Issues Negative Forecast for TELO EarningsTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) - Equities researchers at Zacks Small Cap reduced their Q1 2025 earnings per share (EPS) estimates for shares of Telomir Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Zacks Small Cap analyst B. Sorensen now expeFebruary 7, 2025 | marketbeat.comTelomir Pharmaceuticals (NASDAQ:TELO) Releases Earnings Results, Misses Estimates By $0.05 EPSTelomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05).February 4, 2025 | marketbeat.comTelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in DecemberTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 58.9% from the December 15th total of 799,400 shares. Currently, 7.4% of the company's stock are short sold. Based on an average daily volume of 171,900 shares, the short-interest ratio is currently 7.4 days.January 16, 2025 | marketbeat.comGeode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)Geode Capital Management LLC grew its holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 259.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 238,737 shares of the company's stock afteJanuary 9, 2025 | marketbeat.comShort Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Expands By 22.9%Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 799,400 shares, an increase of 22.9% from the November 30th total of 650,600 shares. Based on an average trading volume of 164,300 shares, the short-interest ratio is currently 4.9 days. Approximately 4.7% of the company's stock are sold short.December 29, 2024 | marketbeat.comWhy Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?December 3, 2024 | benzinga.comWhat is Zacks Small Cap's Forecast for TELO FY2024 Earnings?Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) - Analysts at Zacks Small Cap issued their FY2024 earnings per share estimates for Telomir Pharmaceuticals in a research report issued to clients and investors on Thursday, November 21st. Zacks Small Cap analyst B. Sorensen forecasts thatNovember 25, 2024 | marketbeat.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.8% - Still a Buy?Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 3.8% - Should You Buy?November 12, 2024 | marketbeat.comTelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Large Growth in Short InterestTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 672,400 shares, a growth of 410.9% from the September 15th total of 131,600 shares. Based on an average daily trading volume, of 122,200 shares, the short-interest ratio is currently 5.5 days. Approximately 4.0% of the company's shares are sold short.October 10, 2024 | marketbeat.comTelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Large Increase in Short InterestTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 161,600 shares, an increase of 26.1% from the August 15th total of 128,200 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily volume of 76,500 shares, the short-interest ratio is currently 2.1 days.September 14, 2024 | marketbeat.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 2.2%Telomir Pharmaceuticals (NASDAQ:TELO) Trading 2.2% HigherSeptember 14, 2024 | marketbeat.comTelomir Pharmaceuticals Inc (TELO)September 1, 2024 | investing.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.2%Telomir Pharmaceuticals (NASDAQ:TELO) Trading 3.2% HigherAugust 22, 2024 | marketbeat.comTELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024August 14, 2024 | investorplace.comTelomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher ChapmanAugust 12, 2024 | globenewswire.comTelomir Pharmaceuticals, Inc.'s Lock-Up Period Will Expire on August 7th (NASDAQ:TELO)Telomir Pharmaceuticals' (NASDAQ:TELO - Get Free Report) lock-up period will expire on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its IPO on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.July 31, 2024 | marketbeat.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 15.5%Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 15.5%July 6, 2024 | marketbeat.comTelomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap IndexesJuly 2, 2024 | markets.businessinsider.comTelomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting PanelJune 17, 2024 | globenewswire.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading 2.2% Higher Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Up 2.2%June 14, 2024 | marketbeat.comTelomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1May 30, 2024 | globenewswire.comTELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024May 14, 2024 | investorplace.comTrading was temporarily halted for "TELO" at 11:04 AM with a stated reason of "LULD pause."April 22, 2024 | marketbeat.comTelomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.April 16, 2024 | globenewswire.comTelomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024April 2, 2024 | globenewswire.comUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 29, 2024 | globenewswire.comTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 26, 2024 | globenewswire.comTelomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26thMarch 22, 2024 | globenewswire.comTelomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal ScienceMarch 14, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 7, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 7, 2024 | globenewswire.comMichael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age ReversalMarch 5, 2024 | globenewswire.comTrading was temporarily halted for "TELO" at 10:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 03:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 03:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 02:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 02:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 01:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 01:02 PM with a stated reason of "LULD pause." Trading set to resume at 01:02 PM. February 12, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 11:02 AM with a stated reason of "LULD pause."February 9, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 11:02 AM with a stated reason of "LULD pause."February 9, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 10:02 AM with a stated reason of "LULD pause."February 9, 2024 | marketbeat.com Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address TELO Media Mentions By Week TELO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TELO News Sentiment▼0.000.74▲Average Medical News Sentiment TELO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TELO Articles This Week▼00▲TELO Articles Average Week Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cartesian Therapeutics News Mereo BioPharma Group News Alpha Teknova News Heron Therapeutics News Entrada Therapeutics News Cryoport News Olema Pharmaceuticals News Arcturus Therapeutics News Atai Life Sciences News COMPASS Pathways News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TELO) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TELO Stock Free TELO Stock Alerts